Baabaa,
Amarin has a monopoly on Vascepa until the end of exclusivity/patents. What you suggested was locking up API sources by buying them. A monopoly on EPA is not the same as a monopoly on V.
Could Amarin lock up much of the API in long-term contracts, putting up high barriers for competitors? Absolutely. However if they went too far with this strategy it could potentially lead to antitrust action. I also agree that they could vertically integrate, but doubt its worth the hassle.
In any case, trying to monopolize something so ubiquitous seems futile
Market Data 
Markets 
AI
